(NEW YORK) — Sarah Jessica Parker is ending her relationship with Mylan, the company that makes the life-saving allergy medication-injecting EpiPen, after the company raised the price of its product to more than 500 bucks.
The price hike represents a 450-percent increase since the company began selling the product in 2007 — turning it into a “billion-dollar business,” Bloomberg Businessweek reports.
Parker had taken part in a promotional campaign touting the medicine’s use in counteracting the severe allergic reaction known as anaphlyaxis. Calling the EpiPen a “lifesaving necessity” for people like James Wilkie, her peanut-allergic son with Matthew Broderick, Parker blasted Mylan.
“I’m left disappointed, saddened and deeply concerned by Mylan’s actions,” Parker posted on her Instagram. “I do not condone this decision and I have ended my relationship with Mylan as a direct result of it.”
“I hope they will seriously consider the outpouring of voices of those millions of people who are dependent on the device, and take swift action to lower the cost to be more affordable for whom it is a life-saving necessity,” Parker continued.
Marketing like Mylan’s “Anaphylaxis: For Reel” Initiative in which Parker took part helped make the injector pens seem like must-have accessories for schools and offices all over the country, Bloomberg notes — and in doing so boosted Mylan’s bottom line.
Mylan is currently under congressional scrutiny for the price hike. The company announced Thursday morning they’ll offer a “savings card” to help customers better afford the EpiPen, but stopped short of saying they’d lower the price.
Copyright © 2016, ABC Radio. All rights reserved.